Share this video  

ASCO 2022 | Latest news in HER2-low breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of HER2-low breast cancer, an emerging field in breast cancer therapy. Low expression of HER2 is defined as an IHC score of 1+ or 2+ with a negative in situ hybridization (ISH) test, and recently, the results of DESTINY-Breast04 (NCT03734029) highlight the potential of HER2-targeted therapies in this distinct population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.